Nigeria launched lenacapavir in March 2026 — a long-acting injectable that prevents HIV infection with just two shots per year. The clinical case is compelling. The distribution challenge is enormous.
From a Pill a Day to a Shot Twice a Year
For years, HIV prevention in Nigeria relied on a daily oral tablet — a regimen that worked in clinical trials but struggled in the real world. Adherence rates for oral pre-exposure prophylaxis (PrEP) have been modest across Sub-Saharan Africa, with some studies suggesting fewer than 40% of users maintained consistent daily dosing beyond six months.
Lenacapavir changes the regimen entirely. A healthcare worker administers the injection twice yearly — every six months. No daily pill. No risk of forgetting. For populations at highest risk — young women in high-prevalence areas, key workers, people with HIV-positive partners — the simplified regimen addresses one of the biggest barriers to effective prevention.
The World Health Organization endorsed twice-yearly injectable lenacapavir as an additional PrEP option in July 2025, clearing the path for African regulatory approvals. Nigeria’s National Agency for the Control of AIDS acted quickly, and the first injections were administered in Abuja in late March 2026.
The Science Is the Easy Part
What Nigeria has demonstrated is the ability to approve and introduce a technically sophisticated medical product quickly. What it now faces is the harder problem: delivering that product at scale to the people who need it most.
Nigeria has an estimated population of 220 million. There are roughly two million people living with HIV. The prevention target for lenacapavir — based on WHO guidance — includes the full range of high-incidence groups: sexually active adults in high-prevalence zones, people in serodiscordant relationships, key populations including sex workers and men who have sex with men.
The number of Nigerians who could technically benefit from lenacapavir runs into the millions. The number of Nigerians who will realistically access it within the first year of the programme is likely to be measured in the tens of thousands at best.
Why Access Is the Real Frontier
The gap between clinical approval and population-level access is where Nigeria’s HIV prevention programme has historically struggled. Several structural factors explain why.
First, the product requires trained healthcare workers to administer — it is not a tablet that can be dispensed from a pharmacy counter and taken unsupervised. Building the community health workforce capacity to deliver injections twice yearly across Nigeria’s diverse and often remote geography is a multi-year endeavour.
Second, lenacapavir is currently priced well above what Nigeria’s public health system can afford at generic-tier costs. Gilead Sciences, which holds the patent, has made tiered pricing agreements with several low-income countries, but the actual cost per injection dose remains significant. Without aggressive subsidy from the Global Fund, PEPFAR, or domestic budget allocation, the product will reach primarily those who can pay out of pocket.
Third, the cold chain and supply logistics for a twice-yearly injection are different from those for daily oral PrEP. While the less frequent dosing is an advantage from a patient adherence standpoint, it also means that each clinic visit is higher stakes — a missed appointment means a gap in protection rather than simply a missed daily dose.
Community Perspectives on the Rollout
Nigeria’s HIV civil society organisations have responded to the lenacapavir launch with cautious optimism. The Nigerian Prevention Working Group — a coalition of community-based organisations — has welcomed the introduction but issued a statement calling for “unambiguous equity commitments” from the government and its international partners.
The core demand is simple: the first doses should reach the highest-incidence populations, not the highest-income patients. In practice, that means mobile outreach to young women in the North Central and South South zones, where incidence rates remain stubbornly high despite years of prevention programming. It means programmes that reach sex workers and men who have sex with men — groups that face criminalisation and social stigma that make clinic-based care genuinely inaccessible.
The Regional Picture
Nigeria is not alone in rolling out lenacapavir. South Africa approved the product in late 2025 and began a phased introduction in early 2026. Kenya and Uganda are both in the planning stages for regulatory submission and launch.
What Nigeria does in the next 12 months will be closely watched. If the product reaches the people most affected by the epidemic — rather than concentrating in urban private clinics — it will validate a novel approach to HIV prevention that has the potential to bend the curve of new infections across the continent.
If it does not, the failure will not be of science or medicine. It will be of systems and politics — the familiar African story of a good tool used in a context that was not ready to deploy it at scale.
The injection is there. The question now is who gets it.